Orphazyme acquires CytRx technology

Orphazyme ApS (Copenhagen, Denmark) acquired molecular chaperone regulation technology from CytRx Corp. (NASDAQ:CYTR). The deal includes arimoclomol, a hydroxylamine derivative that induces heat shock protein expression in Phase II testing for amyotrophic lateral sclerosis (ALS). Orphazyme said the technology complements its development of heat shock protein-based therapies, including Orph-001. The recombinant version of the molecular chaperone Hsp70 is in preclinical testing for lysosomal storage diseases. ...